J&J：Complete data for Nipocalimab were announced.
Johnson & Johnson (J&J) Presents Full Data from Phase 2b JASMINE Study of Nipocalimab in Systemic Lupus Erythematosus (SLE) at EULAR 2026
I. Introduction: The SLE Treatment Landscape is Being Reshaped
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease affecting 3-5 million patients worldwide. For decades, treatment relied on steroids and immunosuppressants until belimumab (GSK’s Benlysta®) became the first approved biologic in over 50 years in 2011, followed by anifrolumab (AZ’s Saphnelo®) in 2021.
However, the current standard of care remains far from ideal—a considerable proportion of patients have inadequate responses, and long-term steroid use carries significant metabolic, bone, and infection risks. Against this backdrop, the FcRn blocker Nipocalimab brings a novel mechanism of action to SLE treatment with its JASMINE Phase 2b data.
II. Nipocalimab: What Makes Its Mechanism Different?
Target: Neonatal Fc receptor (FcRn)
Mechanism: FcRn normally protects IgG from lysosomal degradation, prolonging IgG half-life. Nipocalimab blocks FcRn → accelerated clearance of pathogenic IgG autoantibodies → reduced immune complex deposition and inflammation. The advantage is immunoselectivity—it does not broadly suppress the immune system, only clears IgG autoantibodies.
III. JASMINE Phase 2b Data: Core Interpretation
Trial Design: N=228 patients with active moderate-to-severe SLE, 52 weeks, multicenter RCT, dose-finding (15 mg/kg vs placebo). Primary endpoint: SRI-4 response rate at Week 24.
3.1 Overall Population Data
| Endpoint | Nipocalimab | Placebo | Difference |
| Week 24 SRI-4 | 57.9% | 51.1% | +6.8% (statistically significant) |
| Week 52 SRI-4 | 65.4% | 51.5% | +13.9% |
| Week 52 LLDAS | 42.3% | 25.3% | +17.0% |
Interpretation: The 6.8% difference in the overall population at Week 24 may not be dramatic, but statistical significance was achieved. More importantly, efficacy deepened over time—by Week 52, the SRI-4 difference expanded from +6.8% to +13.9%, and the LLDAS difference reached 17%.
3.2 Autoantibody-Positive Subgroup
| Subgroup | Difference in Efficacy |
| Autoantibody-positive (~80% of SLE patients) | +22% |
Interpretation: In the ~80% of SLE patients with autoantibodies (anti-dsDNA, anti-Smith, or ANA positive), the efficacy difference jumped to 22%. This clearly defines the precision patient profile for Nipocalimab—truly IgG-mediated SLE, which aligns with the mechanism of an FcRn blocker.
3.3 Safety
The safety profile was consistent with previous Phase 2 studies, with no new safety signals identified. The most common AEs included nasopharyngitis, headache, UTI, and nausea. No typical safety issues associated with broad-spectrum immunosuppressants were observed.
IV. Comparative Efficacy of Approved SLE Biologics (Indirect Comparison)
| Drug | Mechanism | Key Endpoint Difference vs Placebo | LLDAS Difference |
| Belimumab (BLISS Ph3) | anti-BLyS | SRI-4: ~14-16% | — |
| Anifrolumab (TULIP pooled) | anti-IFNAR | BICLA: ~16% (SRI-4 not met in TULIP-1) | ~17% |
| Nipocalimab (JASMINE Ph2b) | anti-FcRn | SRI-4 (W52): 13.9%; AutoAb+ subgroup: 22% | 17% (W52) |
Key Conclusions
Nipocalimab’s overall population efficacy in SRI-4 and LLDAS is comparable to existing biologics.
In the autoantibody-positive subgroup, its effect may be superior to current standards of care.
V. Emerging Competitors: The Disruptive Potential of CAR-T and TCE
The most exciting developments in SLE treatment are not just iterative improvements in traditional monoclonal antibodies, but the entry of entirely new therapeutic modalities.
5.1 Autologous CD19 CAR-T
Representative pipelines:
KYV-101 (Kyverna Therapeutics): Fully human CD19 CAR-T, entered Ph2/3. Demonstrates deep B cell depletion and reduced disease activity in SLE, with some patients achieving drug-free remission.
GC012F (Gracell, now under AstraZeneca): CD19/BCMA dual-target CAR-T, received SLE IND, Ph1 enrolling.
Erlangen/German study: Mackensen’s team (Nature Medicine 2022) reported long-term drug-free remission in the first 5 SLE patients treated with CAR-T.
CAR-T aims to achieve “immune reset” → long-term drug-free remission or even “functional cure.” However, the cost is high: autologous manufacturing, bridging chemotherapy, CRS/ICANS risks. Currently, it is only for refractory SLE.
5.2 CD19 T Cell Engagers (TCEs)
CLN-978 (Cullinan Therapeutics): CD19×CD3 TCE, subcutaneous administration. At EULAR 2026 this week, Ph1 OUTRACE SLE data were presented with the headline “induces robust B cell depletion.” Subcutaneous dosing and simple manufacturing position it as an “off-the-shelf alternative to CAR-T.”
Genrix Bio: Initiated SLE Ph1 enrollment in China.
Velinotamig (Cullinan): BCMA×CD3 TCE, also advancing.
TCEs pursue deep B cell depletion but face challenges including CRS and infection risks.
5.3 In Vivo CAR-T — The Cutting Edge
In September 2025, NEJM reported that a team from The First Affiliated Hospital of University of Science and Technology of China used lipid nanoparticle (LNP)-delivered mRNA to generate CD19 CAR-T in vivo, without ex vivo modification. After treating refractory SLE patients, B cell depletion and reduced disease activity were observed, with no severe adverse events.
This represents the most aggressive next-generation immunotherapy direction—if the balance of safety and durability is confirmed, it could be a disruptive shock to the entire SLE treatment landscape.
Overall perspective: TCEs, ex vivo CAR-T, and in vivo CAR-T represent different implementation forms of the B cell clearance mechanism. Fundamentally, after B cell clearance, pathogenic antibodies can still circulate for some time. Therefore, Nipocalimab’s mechanism of reducing pathogenic IgG may still have potential for complementarity with B cell clearance therapies.
Buy Nipocalimab from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
